“Does the dose of hydroxyurea correlate with shorter hospital stay and higher fetal hemoglobin levels in patients with sickle cell disease?”
Background & Aims Sickle cell disease (SCD) leads to recurrent vaso-occlusive crises (VOC) and hospitalizations, imposing a substantial healthcare burden. Hydroxyurea (HU) is known to reduce VOC frequency and hospitalization rates in SCD; however, data comparing the impact of different HU doses on l...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis Group
2026-12-01
|
| Collection: | Future Science OA |
| Sujets: | |
| Accès en ligne: | https://www.tandfonline.com/doi/10.1080/20565623.2025.2610223 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|
